Clinical Trial Update: Plasmodium Immunotherapy for Advanced Ovarian Cancer [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for a Plasmodium-based immunotherapy in advanced ovarian cancer, spanning Phase 2 and Phase 3, with enrollment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Plasmodium immunotherapy

Snippet

Sponsor: CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | Conditions: Advanced Ovarian Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING